Tatiana V. Kudling

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer

James H.A. Clubb, Tatiana V. Kudling, Camilla Heiniö et al. · Frontiers in Immunology · 2022 · 47 citations · Full text

Life Sciences, Immunology, Oncology +17

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control

Dafne C.A. Quixabeira, Sadia Zafar, João M. Santos et al. · Frontiers in Immunology · 2021 · 37 citations · Full text

Medicine, Immunology, Oncology +17

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression

Tatiana V. Kudling, James H.A. Clubb, Dafne C.A. Quixabeira et al. · OncoImmunology · 2022 · 35 citations · Full text

Medicine, Immunology, Oncology +17

Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri A. Pakola, Katriina Peltola, James H.A. Clubb et al. · Clinical Cancer Research · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial

Matthew S. Block, James H.A. Clubb, Johanna Mäenpää et al. · Nature Communications · 2025 · 29 citations · Full text

Medicine, Oncology, Pharmacotherapy +17